Heri Herliana

Dr. Heri Herliana

Universitas Padjadjaran, Bandung, Jawa Barat, Indonesia
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2023 in Polymers
Verified
Journal Article
Open access
HHHeri Herliana
Heri Herliana
HYHarmas Yazid Yusuf
Harmas Yazid Yusuf
ALAvi Laviana
Avi Laviana
GWGanesha Wandawa
Ganesha Wandawa
Arief CahyantoArief Cahyanto
Arief Cahyanto
Chitosan and gelatin were the most widely used natural materials in pharmaceutical and medical fields, especially as local hemostatic agents, independently or as a composite material with the addition of other active substances. Chitosan and gelatin have excellent properties in biocompatibility, biodegradability, non-toxicity and water absorption capacity. The objective of this review was to analyze the characteristics of chitosan-gelatin (CG) composite-based biomaterial and its effectivity as a local hemostatic agent. We used PRISMA guidelines and the PICO framework to compile this review. The findings demonstrated that the CG composite-based biomaterial had excellent physical, chemical, mechanical properties and local hemostatic agent activity by adding other active substances such as oxidized fibers (OF), silica nanoparticles (SiNPs), calcium (Ca) and biphasic calcium phosphate (BCP) or by setting the CG composite proportion ratio.

18 July 2024 in Polymers
Verified
Journal Article
Open access
PDF file
HHHeri Herliana
Heri Herliana
HYHarmas Yusuf
Harmas Yusuf
ALAvi Laviana
Avi Laviana
GWGanesha Wandawa
Ganesha Wandawa
BABasril Abbas
Basril Abbas
A hemostatic sponge prototype was successfully synthesized from fish gelatin as an alternative to mammalian gelatin; it was mixed with alginate in certain combinations, double cross-linked with calcium ions, and gamma irradiated at a dose of 20 kGy to improve the characteristics and effectiveness of its function as a local hemostatic agent. There were improvements in the physicochemical and mechanical properties, porosity index, absorption capacity, biodegradation properties, biocompatibility, and hemocompatibility of the fish gelatin–alginate sponge (FGAS) prototypes compared with the pure fish gelatin sponge. Hemostatic activity tests showed that the means for clotting time, prothrombin time, and activated partial thromboplastin time were shorter in the FGAS prototype than in the negative control, and there was no significant difference compared with the commercial gelatin sponge. The hemostatic mechanism of the FGAS prototype combined a passive mechanism as a concentrator factor and an active mechanism through the release of calcium ions as a coagulation factor in the coagulation cascade process.

14 May 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
HHHeri Herliana
Heri Herliana
HYHarmas Yusuf
Harmas Yusuf
ALAvi Laviana
Avi Laviana
GWGanesha Wandawa
Ganesha Wandawa
BABasril Abbas
Basril Abbas
A hemostatic sponge prototype was successfully synthesized from fish gelatin as an alternative to mammalian gelatin, which was mixed with alginate in certain combinations and double cross-linking of calcium ions and gamma irradiation at a dose of 20 kGy to improve the characteristics and effectiveness of its function as a local hemostatic agent. There was an improvement in the physicochemical and mechanical properties, porosity index, absorption capacity, biodegradation properties, biocompatibility, and hemocompatibility of the FGAS prototypes compared with the pure fish gelatin sponge. Hemostatic activity tests showed that the means of clotting time, prothrombin time, and activated partial thromboplastin time were shorter in the FGAS prototype than in the negative control, and there was no significant difference compared with the commercial gelatin sponge. The hemostatic mechanism of the FGAS prototype combined a passive mechanism as a concentrator factor and an active mechanism through the release of calcium ions as a coagulation factor in the coagulation cascade process.